Investigating genetic risks and long-term effects of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors
This study is looking at how our genes might play a role in causing Stevens-Johnson syndrome and toxic epidermal necrolysis, serious skin reactions often caused by medications, by analyzing DNA from survivors to help find ways to better prevent and treat these conditions for people who might be at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-10441271 on NIH RePORTER |
What this research studies
This research focuses on understanding the genetic factors that contribute to Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), severe skin reactions often triggered by medications. By analyzing DNA samples from survivors, the study aims to identify specific genetic markers that increase the risk of these conditions and assess the long-term health impacts on affected individuals. The research utilizes a registry developed by the SJS Foundation to create a comprehensive data and DNA biobank, which will help in understanding the prevalence and genetic associations of SJS/TEN in diverse populations. This approach seeks to improve preventive measures and treatment options for patients at risk.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced Stevens-Johnson syndrome or toxic epidermal necrolysis, particularly those with a history of drug exposure.
Not a fit: Patients who have not experienced SJS or TEN, or those whose conditions are unrelated to drug exposure, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better identification of individuals at risk for SJS/TEN and improved strategies for prevention and management of these severe conditions.
How similar studies have performed: Previous research has shown promising results in identifying genetic markers associated with drug-induced SJS/TEN, but this study aims to expand on those findings in underrepresented populations.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Phillips, Elizabeth — Vanderbilt University Medical Center
- Study coordinator: Phillips, Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.